Keywords
Immunosuppression
Kidney transplantation
Multiple myeloma
Smoldering multiple myeloma
Case Report
Categories
How to Cite
Abstract
Chronic kidney disease and end-stage kidney disease are frequently observed in patients with plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma, although kidney failure is not always directly attributable to the hematologic disorder. Kidney transplantation represents the treatment of choice for end-stage kidney disease; however, the presence of an underlying plasma cell disorder poses significant clinical challenges and may limit access to transplantation.
We report the case of a 73-year-old woman with end stage kidney disease and low-risk smoldering multiple myeloma who underwent a comprehensive pre-transplant evaluation, including a kidney biopsy that excluded myeloma-related nephropathy and supported a non–plasma cell–related etiology of kidney failure.
The patient subsequently underwent deceased-donor dual kidney transplantation. Seventeen months after transplantation, she progressed from smoldering multiple myeloma to symptomatic multiple myeloma, requiring chemotherapy with a bortezomib-, thalidomide-, and dexamethasone-based regimen. Treatment resulted in a very good partial hematologic response according to International Myeloma Working Group criteria, accompanied by stable kidney graft function.
This case suggests that kidney transplantation may be feasible in carefully selected patients with SMM following thorough pre-transplant evaluation. However, it also highlights substantial risks of post-transplant disease progression and malignancy, underscoring the need for rigorous risk stratification, multidisciplinary decision-making, and close post-transplant surveillance.
References
1. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ, 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007: 2582 [PMID: 17582068, https://doi.org/10.1056/NEJMoa070389]
2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014: e538 [PMID: 25439696, https://doi.org/10.1016/S1470-2045(14)70442-5]
3. Lussier T, Schoebe N, Mai S. Risk Stratification and Treatment in Smoldering Multiple Myeloma. Cells. 2021: 130 [PMID: 35011692, https://doi.org/10.3390/cells11010130]
4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ, 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006: 1362 [PMID: 16571879, https://doi.org/10.1056/NEJMoa054494]
5. Burwick N, Adams SV, Todd-Stenberg JA, Burrows NR, Pavkov ME, O'Hare AM. Association of Monoclonal Gammopathy with Progression to ESKD among US Veterans. Clin J Am Soc Nephrol. 2018: 1810 [PMID: 30442867, https://doi.org/10.2215/CJN.06210518]
6. Vakiti A, Padala SA, Hashmi MF, Mewawalla P. Renal Disease in Monoclonal Gammopathies. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
7. Blum A, Bazou D, O'Gorman P. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood Lymphat Cancer. 2018: 21 [PMID: 31360091, https://doi.org/10.2147/BLCTT.S136447]
8. Clari R, Tarella C, Giraudi R, Torazza MC, Gallo E, Lavacca A, Fop F, Mella A, Dolla C, Biancone L. Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome. Clin Kidney J. 2021: 317 [PMID: 33564434, https://doi.org/10.1093/ckj/sfaa105]
9. Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol. 2012: 365 [PMID: 22473253, https://doi.org/10.1159/000337482]
10. Bhasin B, Szabo A, Wu R, Saad ER, Hari P, Dhakal B, Chhabra S, D'Souza A. Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clin Lymphoma Myeloma Leuk. 2020: e468 [PMID: 32340914, https://doi.org/10.1016/j.clml.2020.02.019]
11. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008: 11 [PMID: 18808676, https://doi.org/10.1186/1471-2369-9-11]
12. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, Duong van Huyen JP, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018: 293 [PMID: 29243394, https://doi.org/10.1111/ajt.14625]
13. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996: 235 [PMID: 8807593, https://doi.org/10.1038/ki.1996.307]
14. Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020: S11 [PMID: 32301874, https://doi.org/10.1097/TP.0000000000003136]
15. Massicotte-Azarniouch D, Noel JA, Knoll GA. Epidemiology of Cancer in Kidney Transplant Recipients. Semin Nephrol. 2024: 151494 [PMID: 38538455, https://doi.org/10.1016/j.semnephrol.2024.151494]
16. Aslam N, Trautman CL, Sher T. Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. Transplant Direct. 2021: e723 [PMID: 34263021, https://doi.org/10.1097/TXD.0000000000001176]
17. Bancu I, Canas L, Juega FJ, Perez M, Malumbres S, Bonet J, Lauzurica R. Outcomes of Monoclonal Gammopathy of Undetermined Significance in Patients Who Underwent Kidney Transplantation. Transplant Proc. 2015: 2344 [PMID: 26518922, https://doi.org/10.1016/j.transproceed.2015.08.023]
18. Alfano G, Fontana F, Colaci E, Messerotti A, Bettelli F, Potenza L, Luppi M, Cappelli G. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience. Transplantation. 2017: e337 [PMID: 28731904, https://doi.org/10.1097/TP.0000000000001884]
19. Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020: 102 [PMID: 33067414, https://doi.org/10.1038/s41408-020-00366-3]
20. Kormann R, Pouteil-Noble C, Muller C, Arnulf B, Viglietti D, Sberro R, Sayegh J, Durrbach A, Dantal J, Girerd S, Pernin V, Albano L, Rondeau E, Peltier J. Kidney transplantation for active multiple myeloma or smoldering myeloma: a case-control study. Clin Kidney J. 2021: 156 [PMID: 33564414, https://doi.org/10.1093/ckj/sfz128]
21. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, Galende J, Martin-Nunez G, Alonso JM, de Las Heras N, Hernandez JM, Martin A, Lopez-Berges C, Orfao A, San Miguel JF. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007: 2586 [PMID: 17576818, https://doi.org/10.1182/blood-2007-05-088443]
22. Passweg J, Thiel G, Bock HA. Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients. Nephrol Dial Transplant. 1996: 2461 [PMID: 9017623, https://doi.org/10.1093/oxfordjournals.ndt.a027215]
23. Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR. Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. Eur J Haematol. 2016: 439 [PMID: 26872804, https://doi.org/10.1111/ejh.12748]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Sonila Mocka MD, Stefano Ferraro MD, Matteo Trezzi MD, Cristina Rossi MD